PeptideScanner

Crossref Research Integrity v1

When a source changes,
the notice travels with it.

PeptideScanner checks DOI-backed publications used in supervised synthesis against a dated Crossref work snapshot. Publisher errata, corrections, expressions of concern, retractions, and reinstatements remain attributed source events—not silent edits or PeptideScanner judgments.

37Reviewed syntheses
97DOI-backed checks
6Registered notices
4Unavailable DOI matches

Attributed source notices

Registered updates in the reviewed set

See alongside PeptideScanner changes →

Publisher metadata · Correction

Survodutide

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Publication DOI
10.1038/s41591-026-04479-3
Notice DOI
10.1038/s41591-026-04650-w ↗
Crossref dates
August 25, 2026
Checked
September 15, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Publisher metadata · Erratum

Cagrilintide

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Publication DOI
10.1016/s2213-8587(26)00125-7
Notice DOI
10.1016/s2213-8587(26)00157-9 ↗
Crossref dates
June 19, 2026 and August 1, 2026
Checked
September 15, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Publisher metadata · Erratum

Survodutide

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

Publication DOI
10.1016/s2213-8587(23)00356-x
Notice DOI
10.1016/s2213-8587(25)00399-7 ↗
Crossref dates
December 17, 2025 and February 1, 2026
Checked
August 19, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Publisher metadata · Erratum

Setmelanotide

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

Publication DOI
10.1016/s2213-8587(22)00277-7
Notice DOI
10.1016/s2213-8587(22)00360-6 ↗
Crossref dates
February 1, 2023
Checked
August 19, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Publisher metadata · Erratum

Octreotide

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

Publication DOI
10.1016/s2213-8587(21)00296-5
Notice DOI
10.1016/s2213-8587(22)00051-1 ↗
Crossref dates
March 1, 2022
Checked
August 19, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Publisher metadata · Erratum

Tirzepatide

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Publication DOI
10.1016/s0140-6736(21)01324-6
Notice DOI
10.1016/s0140-6736(21)01556-7 ↗
Crossref dates
July 17, 2021
Checked
August 19, 2026

Crossref metadata establishes that this notice is connected to the publication. It does not, by itself, establish what text or result changed or how the source should be interpreted.

Bounded cohort

Every reviewed synthesis publication

Coverage is limited to PubMed sources explicitly selected for the 37 supervised syntheses. It does not yet cover all 1,447 public PubMed bibliography records.

Method and source boundary

How v1 works

Each accepted PubMed payload supplies the DOI-to-PMID link. PeptideScanner then validates the exact Crossref work DOI, retains the response SHA-256 and Crossref indexing instant, and normalizes only supported updated-by metadata. Repeated entries for the same notice are combined by DOI, type, label, and source while every distinct upstream date remains visible.

Crossref says its REST API exposes metadata deposited by members and trusted sources, including Retraction Watch. The Retraction Watch dataset is updated each working day, but its corrections and expressions-of-concern coverage is not comprehensive. PeptideScanner stores no Crossref abstracts and does not infer the substance or importance of a notice from metadata alone.

Read Crossref's Retraction Watch documentation ↗

Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance